Ethnobridging Trial carried out in collaboration with Merck published in The European Journal of Clinical Pharmacology

On September 7, 2011,in Eur J Clin Pharmacol DOI 10.1007/s00228-011-1127-z

Cypress, CA, September 29, 2011

West Coast Clinical Trials, LLC (WCCT) is pleased to announce the publication of the ethnobridging Pharmacokinetic-Pharmacodynamic study of the novel, orally bioavailable, anti-platelet drug, vorapaxar, carried out in collaboration with Merck, Sharp and Dohme Corp (Eur J Clin Pharmacol DOI 10.1007/s00228-011-1127). Vorapaxar is now in late Phase III clinical development for the prevention and treatment of atherothrombotic disease.  WCCT carried out the clinical portion of this important ethnobridging trial which demonstrated that vorapaxar produced rapid, complete, and sustained inhibition of TRAP-induced platelet aggregation when administered as a single dose of 40 mg or as multiple once-daily 2.5 mg doses with no apparent differences between Japanese and Caucasian subjects.

More About WCCT

WCCT is an early phase drug development clinical Contract Research Organization, based in the United States with 150 beds in 2 locations.  As a drug development partner, WCCT Global works with domestic and foreign innovator companies who need regulatory and strategic development support from First-in-Man thru the proof of concept stage. WCCT Global specializes in special patient population phase I studies that require complex study designs and procedures, including thorough QTc and ethnobridging trials. WCCT has conducted dozens of ethnobridging trials in the last few years, helping to expedite drug approval globally and moving NCEs towards market approval in late phase research. Asian bridging studies have been proven to add more value to NCEs; WCCT Global can contract and draft a complete Phase I program which incorporates Asian patients, including Japanese, Chinese, and Korean cohorts.

WCCT has the distinct advantage of being located in a very ethnically diverse metropolitan area, with easy access to a large amount of Normal Healthy Volunteers of varying ethnic backgrounds including Caucasian, Asian, African American, and Hispanic in the Los Angeles and Orange County regions.

Contact: mgr@wcct.com for more information on WCCT’s Ethnobridging Trial Capabilities